One study demonstrated that treatment with mTOR kinase inhibitors resulted in elevated expression levels of cleaved caspase 3 proteins and dramatically downregulated Bcl-2 levels when mTOR was downregulated in human laryngocarcinoma and lung cancer [51,52]. This evidence concerns the gene BCL2 and lung carcinoma.